1q21.1 deletion syndrome

Lore & Background

The 1q21.1 deletion syndrome was first described in 2008, when chromosomal microarray studies identified a recurrent microdeletion in the distal 1q21.1 region. The deletion typically spans 1.35 Mb and affects one copy of chromosome 1 in each cell. The syndrome is caused by the loss of multiple genes in this region, though researchers are still working to determine which specific missing genes contribute to the observed characteristics. Because some individuals with the deletion show no clear traits, additional genetic and environmental factors are thought to influence symptom development.

Signs and symptoms are highly variable. Approximately 75% of children exhibit delayed motor development, and about 30% have mild learning difficulties. Microcephaly is reported in 39% of cases, and seizures affect roughly 16% of children, typically beginning in infancy. Psychiatric and behavioral abnormalities can include autism spectrum disorder, attention deficit hyperactivity disorder, mood disorders, and schizophrenia. Physical findings may include craniofacial dysmorphism, cardiac septal defects, genitourinary abnormalities, and eye problems such as strabismus or cataracts. The syndrome can have completely different effects on members of the same family.

Diagnosis is confirmed by detecting the recurring distal 1.35-Mb heterozygous deletion within the position of 145–146.35 Mb on chromosome 1, using chromosome microarrays or fluorescence in situ hybridization. Management depends on individual symptoms and may include ophthalmologic, cardiac, developmental, neurological, and psychiatric evaluations, as well as brain imaging and renal ultrasounds. Occupational and physical therapy, special learning programs, and feeding therapy may be used to address specific needs.

Reader's Guide

1q21.1 deletion syndrome is significant as a model of genomic disorder with incomplete penetrance and variable expressivity. Its discovery in 2008 via chromosomal microarray studies highlighted the power of modern genomic technologies to identify recurrent copy number variations associated with neurodevelopmental and psychiatric conditions. The syndrome's association with schizophrenia—found in 0.2%-0.6% of those with distal 1q21.1 deletions—and with autism spectrum disorder underscores the genetic overlap between these conditions. Research on the BCL9 gene within the deleted region has linked common variations to schizophrenia risk, while studies of DUF1220 protein domains, which are abundant in the 1q21.1 region, suggest a role in brain size and cognitive development. The syndrome's legacy lies in advancing understanding of how specific chromosomal deletions can produce a wide spectrum of outcomes, from normal function to significant disability, and in informing genetic counseling for affected families. Its rarity—only 102 identified cases as of 2024—means that much remains unknown, and ongoing research aims to clarify the contributions of individual genes and environmental factors.

Did You Know?

• As of 2024, only 102 people with 1q21.1 deletion syndrome have been identified in medical research.
• Approximately 75% of children with the deletion exhibit delayed motor development, such as sitting, standing, and walking.
• The syndrome is estimated to occur in about 0.015% of the population, but actual prevalence may be higher due to incomplete penetrance.
• Distal 1q21.1 microdeletions have been found in 0.2%-0.6% of individuals with schizophrenia.

Discovery, Nomenclature & Rarity

The story of 1q21.1 deletion syndrome began in 2008, when chromosomal microarray research published simultaneously in Nature Genetics and the New England Journal of Medicine revealed a recurrent microdeletion on chromosome 1. Before that landmark year, this specific chromosomal gap had no name and no recognized clinical profile. The nomenclature itself is a compact map: the leading '1' identifies chromosome 1, the letter 'q' designates the long arm of that chromosome, and '21.1' pinpoints the precise segment along that arm where the missing sequence resides. The condition is classified as a distal deletion within the broader family of 1q21.1 copy number variations. In practical terms, a person with the syndrome carries one full-length chromosome 1 and one shortened partner in which a stretch of genetic material is absent. Despite two decades of research, the condition remains extraordinarily rare; as of 2024, medical literature has documented only 102 confirmed individuals, underscoring how little is still known about its full clinical picture.

A Mosaic of Symptoms

One of the most striking features of 1q21.1 deletion syndrome is its extraordinary clinical variability. Roughly three-quarters of affected children experience developmental delays, particularly in milestones like sitting, standing, and walking, while approximately 30 percent carry a diagnosis of mild learning difficulties. Yet other individuals with the same deletion function without any apparent impairment, and even siblings within a single family can present with entirely different symptom profiles. Microcephaly appears in about 39 percent of cases, and craniofacial traits, though common, are so heterogeneous that they resist easy pattern recognition. Neurologically, hypotonia and tremors are frequent, and roughly 16 percent of children develop seizures, usually emerging in infancy. Psychiatric manifestations span autism spectrum disorder, ADHD, mood and anxiety disorders, and, in some adults, psychotic conditions; distal 1q21.1 deletions have been detected in 0.2 to 0.6 percent of individuals with schizophrenia. Beyond the nervous system, the syndrome can involve the heart (septal defects, tetralogy of Fallot), the eyes (strabismus, coloboma, cataracts in about one-third of patients), the genitourinary tract (vesicoureteral reflux, hydronephrosis, cryptorchidism), and the gastrointestinal system, where severe feeding difficulties may necessitate G-tube nutrition.

Genetic Architecture & Inheritance

Genetically, 1q21.1 deletion syndrome follows an autosomal dominant pattern, meaning a single altered copy of chromosome 1 is sufficient to produce the condition. The deleted segment most commonly spans approximately 1.35 megabases—roughly 1.35 million base pairs—within the q21.1 region, though the precise length varies among individuals, with reported sizes ranging from 1.0 to 1.9 megabases. Mefford and colleagues have proposed 1.35 megabases as the reference standard for the typical deletion. Inheritance patterns are mixed: between 18 and 50 percent of cases arise as de novo events, occurring spontaneously in the affected individual, while the remaining 50 to 82 percent are passed down from a parent who may carry the same deletion with little or no visible effect. The underlying mechanism is believed to involve the simultaneous loss of multiple genes within the deleted stretch, though researchers are still working to identify which specific genes drive particular clinical features. The fact that some carriers show no discernible symptoms at all has led to the hypothesis that additional genetic modifiers and environmental influences shape the final phenotype.

Diagnosis & the Challenge of Differentiation

Confirming a diagnosis of 1q21.1 deletion syndrome hinges on detecting the recurring distal 1.35-megabase heterozygous deletion located between positions 145 and 146.35 megabases in the reference genome. In practice, clinicians rely on chromosome microarray analysis or targeted fluorescence in situ hybridization to measure copy number and verify the missing segment. A critical step in the diagnostic workup is distinguishing this condition from 22q11.2 microdeletion syndrome, which overlaps in several key features including developmental delay, learning difficulties, intellectual disability, and behavioral deviations. However, individuals with the 1q21.1 deletion lack the distinctive facial characteristics that are hallmarks of the 22q11.2 condition, providing an important clinical differentiator. Because the syndrome's full spectrum of manifestations is still being mapped, management is inherently multidisciplinary. Evaluations typically span ophthalmology, cardiology, developmental pediatrics, neurology, and psychiatry, tailored to the individual's specific needs. The rarity of the condition means that no single treatment protocol exists, and care plans must be assembled case by case.

Gallery